Review Article
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice
Kelley D. Mayden,(1) DNP, APRN-FNP, AOCNP®, John M. Kelton,(2) PharmD, Joanne C. Ryan,(2) PhD, RN, and Ali McBride,(3,4) PharmD, BCPS, BCOP
From (1)Ballad Health Cancer Care, Bristol, Virginia; (2)Pfizer Inc, New York, New York; (3)Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona; (4)University of Arizona Cancer Center, Tucson, Arizona
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Kelley D. Mayden, DNP, APRN-FNP, AOCNP®, 1 Medical Park Boulevard, Bristol, TN 37620. E-mail: kdunrun@charter.net
J Adv Pract Oncol 2022;13(4):417–439 |
https://doi.org/10.6004/jadpro.2022.13.4.5 |
© 2022 Harborside™
ABSTRACT
In oncology practices across the United States, biosimilars—highly similar versions of licensed, innovator (reference) biological medicines—are currently emerging as more affordable therapeutic options. Only after a rigorous product development program, during which a proposed biosimilar is analyzed and compared with its reference biologic to demonstrate comparable clinical efficacy, safety, and tolerability, is biosimilarity supported and licensure granted by the US Food and Drug Administration. Coincidentally, many advanced practitioners (APs) are finding themselves at the forefront of introducing monoclonal antibody (mAb) biosimilars in their oncology practice. Advanced practitioners are often tasked with building the confidence of colleagues and patients who may be unfamiliar with biosimilars, skeptical about integrating them, or have yet to consider mAb biosimilars as a viable and more sustainable cancer treatment option. With this responsibility comes a number of challenges that require APs to become knowledgeable about biosimilars and approaches to their implementation. This review aims to highlight the practical implications of streamlining the integration of biosimilar therapies in an oncology practice.
For access to the full length article, please
sign in.
